AFFILIATIONS
1 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
2 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
3 Genetron Health (Beijing) Co. Ltd., Beijing, China
4 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
5 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
6 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
7 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
8 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
9 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
10 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
11 Genetron Health (Beijing) Co. Ltd., Beijing, China
12 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
13 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
14 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
ABSTRACT
Background: Frontline chronic lymphocytic leukemia (CLL) therapy has shifted toward targeted agents; however, deep remission after a finite treatment course remains clinically relevant. Flow cytometry (FCM) detects measurable residual disease (MRD) to 10-4(MRD4); Immunoglobulin-based next-generation sequencing (IG-NGS) extends sensitivity to 10-6 (MRD6), identifying residual clones in FCM-negative samples. Deeper MRD carries incremental prognostic value in fixed-duration regimens (CLL14; MURANO). We used IG-NGS to characterize measurable residual disease (MRD) depth, tissue concordance, and kinetics across three time-limited strategies.
Methods: We analyzed 103 previously untreated patients in three fixed-duration FCR-backbone strategies: (1) standard FCR (fludarabine, cyclophosphamide, rituximab; 4-6 cycles); (2) the HAMBURGER regimen (continuous ibrutinib alternating with three intermittent FCR cycles administered on days 1–3 of cycles 1, 5, and 9; NCT03980002); (3) the STOP regimen (12-month zanubrutinib lead-in followed by four cycles zanubrutinib plus FCG (G=obinutuzumab), NCT05287984). Patient-specific IGH/IGK/IGL clonotypes were longitudinally tracked in peripheral blood (PB) and bone marrow (BM) using FlorenTrack™ (formerly Seq-MRD®), an ultra-deep clonotype-based IG-NGS MRD assay. uMRD4/uMRD5/uMRD6 required MRD below 10-4/10-5/10-6with the sample limit of detection reaching the corresponding threshold. Flow-NGS concordance, PB-BM used strictly matched same-patient, same-date, same-tissue pairs.
Results: Among 753 post-treatment NGS samples, uMRD4/uMRD5/uMRD6 rates were 266/753 (35.3%)/205/749 (27.4%)/68/674 (10.1%). Across 592 identical FCM-NGS specimens, MRD4 agreement was 90.5% (kappa=0.801); NGS detected MRD4 in 47/246 (19.1%) FCM-negative samples, including 33/110 (30.0%) BM samples. Among 205 PB-BM pairs from 75 patients, continuous MRD correlated strongly (Spearman r=0.916); MRD4 agreement was 191/205 (93.2%; kappa=0.854), with PB-negative/BM-positive results in 12 pairs versus PB-positive/BM-negative results in 2 (McNemar P=.0129).
Best uMRD4/uMRD5/uMRD6 rates were 4/17 (23.5%)/3/17 (17.6%)/2/17 (11.8%) with FCR, 18/37 (48.6%)/11/37 (29.7%)/8/37 (21.6%) with HAMBURGER regimen, and 41/41 (100%)/39/41 (95.1%)/28/41 (68.3%) with STOP regimen (all overall P<.001). In 40 STOP-cohort pairs, tracked clonal burden decreased from 0.414 after zanubrutinib lead-in/before FCG to 4.07×10?6 after at least two zanubrutinib plus FCG (ZFCG) cycles, a median within-patient 8.1×104-fold reduction. Paired uMRD4 increased from 1/40 (2.5%) to 33/40 (82.5%; P<0.001). Among 87 patients with response and MRD4 data, 17/60 (28.3%) complete responders remained MRD4-positive, whereas 16/27 (59.3%) patients without complete response achieved uMRD4. MRD4 recurrence occurred in 7/11 (63.6%) HAMBURGER versus 1/32 (3.1%) ZFCG patients, rising at deeper thresholds. Treatment cohort was associated with progression-free survival (log-rank P<0.001); TP53 abnormality showed an exploratory association with inferior overall survival after cohort stratification (P=0.027). With limited follow-up time, no MRD4/5/6 variable remained significant after cohort adjustment and multiple testing.
Conclusions: Across three time-limited CLL strategies, ultra-deep clonotype NGS resolved disease missed by FCM and identified PB-BM discordance. Sequential STOP regimen achieved the deepest, most consistent molecular remissions among three fixed-duration strategies, but this should not be attributed to treatment sequencing alone: paired analysis localized most clonal clearance to the period after chemoimmunotherapy was added, indicating that chemotherapy-mediated debulking together with the stronger clearance of obinutuzumab relative to rituximab, while zanubrutinib lead-in first lowered tumor burden to enable it — additive contributions whose weights require randomized evaluation. FCM negativity at 10-4 is insufficient to guide discontinuation, since nearly one-third of FCM-negative marrows harbored NGS-detectable disease; Clinical response and molecular remission are not interchangeable and should be applied jointly in stopping rules. MRD recurrence after deep negativity precedes progression, supporting IG-NGS monitoring in fixed-duration CLL.
DISCLOSURES
Yuting Yan, MD: No relevant conflicts of interest to declare.